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Abstract: Recent clinical trials have shown that adoptive chimeric antigen receptor (CAR) T cell
therapy is a very potent and possibly curative option in the treatment of B cell leukemias and
lymphomas. However, targeting a single antigen may not be sufficient, and relapse due to the
emergence of antigen negative leukemic cells may occur. A potential strategy to counter the outgrowth
of antigen escape variants is to broaden the specificity of the CAR by incorporation of multiple antigen
recognition domains in tandem. As a proof of concept, we here describe a bispecific CAR in which
the single chain variable fragment (scFv) is replaced by a tandem of two single-antibody domains or
nanobodies (nanoCAR). High membrane nanoCAR expression levels are observed in retrovirally
transduced T cells. NanoCARs specific for CD20 and HER2 induce T cell activation, cytokine
production and tumor lysis upon incubation with transgenic Jurkat cells expressing either antigen or
both antigens simultaneously. The use of nanobody technology allows for the production of compact
CARs with dual specificity and predefined affinity.
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1. Introduction
Adoptive chimeric antigen receptor (CAR) T cell therapy seems to be remarkably effective for
acute lymphoblastic leukemia (ALL). CD19 CAR T cells eradicate late stage leukemia in 70–90% of
treated patients. The main cause of failure of CAR T cell therapy is antigen escape, yielding CD19
negative leukemic cells that are no longer susceptible to CD19 CAR T cells. Up to 30% of relapsed
ALL patients have been reported to be due to loss or downregulation of the CD19 epitope. CD19
antigen escape can arise by different mechanisms, including differential splicing, missense mutations,
or lineage switch [1–8]. Antigen escape is not unique to CAR therapy and has been reported for
other targeted therapies, such as serine/threonine-protein kinase B-raf (BRAF) inhibitors and PD1
blockade [9–11]. These observations highlight the universal potential of tumor cells to undergo tumor
editing during targeted therapies.
Targeting two or more antigens simultaneously could be an option to reduce outgrowth of antigen
escape variants causing relapse and treatment failure. This has been shown earlier in the context of
targeted immunotoxin treatments [12–14]. Different CAR approaches have been tested to achieve
bispecificity by (i) mixing two T cell lines, each expressing one CAR specific for one antigen (mixing);
(ii) transducing T cells to simultaneously express two different CARs (dual signaling CAR, combining)
or (iii) transducing T cells to express one single CAR that consists of two antigen-binding domains in
tandem (TanCAR, multiplexing). Each approach has its advantages and shortcomings. It has been
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shown that mixing different CAR T cell populations may result in the preferential outgrowth of just
one CAR T cell population. The dual signaling CAR approach is severely compromised by the limited
packaging size of viral vectors [15–17]. On the other hand, multiplexing of CARs has been successful
for the combination of CD19 and HER2/neu and for CD20 and CD19 [17,18]. Other combinations
have been published [19]. The bispecific CARs or TanCARs were able to recognize antigens in a
Boolean OR-gate fashion: either antigen was sufficient to induce robust T cell activation, expansion
and function. When both antigens were presented, a synergistic effect was observed [17,18]. However,
the generation of TanCARs is challenging due to the potential cross-pairing between the variable light
(VL) and variable heavy (VH) chains of different scFvs and the variable loss of affinity that may occur
in the design of the scFvs [15,20]. In addition, there is also a restraint on the size due to the limited
packaging capacity of retroviral vectors [21,22].
As an alternative to scFvs, nanobodies can be used. Nanobodies consist of the VH domain of
heavy chain only antibodies of Camilidae. The heavy chain only antibodies were first described by
Hamers-Castermans [23]. Further characterization revealed the special structure of these antibodies;
they are composed of two heavy chains in which the CH1 domain is lacking. Due to the absence of
the CH1 domain, the antibodies do not have a light chain. As a result, the antigen-binding capacity is
confined to only one variable domain and not two. These single antigen-binding domains can be cloned,
easily expressed and retain the affinity for the specific antigen [24,25]. Their strict monomeric behavior
and their small size makes them ideal building blocks for multidomain constructs. Nanobodies do not
interact with each other. Recent clinical trials have shown possible success with multidomain nanobody
based drugs [26,27]. The use of mouse based scFvs can result in human anti-mouse antibodies.
This immunogenicity can lead to adverse events and loss of efficacy during CAR therapy [28,29].
Nanobodies, on the other hand, are only weakly immunogenic, due to extensive sequence identity
with the human VH gene family III [24,25]. In addition, Vincke et al. have developed a humanized
scaffold nanobody onto which the antigen-binding loops of specific nanobodies can be grafted [30].
Clinical trials have shown virtually absent anti-nanobody antibody induction [26,27].
Long lasting remission seems to be dependent on long term persistence of CAR T cells. Long
term survival of T cells depends on the exhaustion profile of the infused T cells [7,31]. Long et al.
have shown that CAR aggregation on the cell membrane may result from interactions within the scFv
framework and induces CAR CD3ζ domain phosphorylation, tonic T cell activation and ultimately T
cell exhaustion [31]. It was described earlier that scFvs have a strong tendency to self-aggregate [32].
Nanobodies could offer a solution to this issue as nanobodies are single domain antigen-binding
moieties hat do not interact with one another. These characteristics makes nanobodies ideal building
blocks for CARs. Monospecific nanobody based CARs have been generated earlier and showed similar
functionality as scFv-based CARs [33–36].
As a proof of principle, we generated and validated a bispecific CAR, based on nanobodies
(nanoCAR). The variable domains of the scFv were replaced by two nanobody VHs, each specific
for a different antigen: CD20 and HER2. T cells expressing the bispecific nanoCAR were able to
kill tumor cells expressing CD20, HER2 or both. The affinity of the nanoCAR for the antigen was
similar to the original nanobodies, allowing the straightforward design of a bispecific CAR with
predetermined affinities.
2. Results and Discussion
We first validated the CD20 and HER2 monomeric nanoCARs. The coding sequence for the
specific nanobody was inserted in the retroviral plasmid encoding a CAR consisting of the human
IgG1 CH2CH3 (Fc) spacer, the CD28 transmembrane domain, the CD28 and the CD3ζ intracellular
signalling domain (Figure 1A). We generated a bispecific nanoCAR subsequent to validation of the
monomeric nanoCAR. The nanobody targeting CD20 was linked through the structural upper hinge
of the lama IgG2a with the HER2 specific nanobody (Figure 1A). Peripheral blood derived CD4+ and
CD8+ T cells were subsequently transduced to express a CD20 nanoCAR, a HER2 nanoCAR and
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the bispecific nanoCAR. T cells expressing the CARs were sorted and expanded. NanoCARs were
expressed at a similar or higher level, compared to an scFv-based CAR (Figure 1B). More importantly,
the bispecific nanoCAR was stably expressed at high levels.
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Figure 1. Nano chimeric antigen receptorS (CARs) are stably expressed on T cells at levels comparable
to an scFv based CAR. (A) Scheme of the second generation nanoCAR constructs used to retrovirally
transduce T cells. The antigen-binding domain is linked to the constant regions of the Fc tail of the
human IgG1 antibody heavy chain, which is linked to the transmembrane and intracellular CD28
and intracellular CD3ζ chain. (B) Human peripheral blood T cells were activated and retrovirally
transduced to express a nanoCAR. CAR expression was measured by flowcytometry on eGFP+ sorted
cells after staining with a phycoerythrin (PE)-conjugated human anti-IgG antibody, which binds the
spacer domain in the CAR. Non-transduced and scFv-CAR transduced T cells were used as controls.
The figure is representative of five different healthy donors.
To accurately determine the ac ivity of the CAR T c lls, we generat d Jurkat lines expressing
CD20 (CD20+), HER2 (HER2+) or both (CD20+HER2+). These Jurkat lines were used as targets in all
of our experiments. Wild type Jurkat cells do not express CD20 or HER2. We generated three stable
transgenic Jurkat clones expressing CD20, HER2, or both, at similar levels. In this way, we could
exclude a possible effect of antigen density on CAR function. Non-transduced Jurkat cells were used
as an antigen negative control (Figure 2).
We first evaluated the cytotoxic activity of nanoCAR transduced T cells in a standard 4 h
chromium-51 release assay (Figure 3). Non-transduced T cells were not able to lyse antigen positive
cell lines. We saw robust killing of antigen positive cells by the monospecific and bispecific nanoCAR
T cells. The cytotoxic activity was nanoCAR and antigen related since antigen negative Jurkat cells
and non-transduced T cells did not elicit cell lysis. While the tandem nanoCAR T cells killed HER2
postive Jurkat cells in the same fashion as the HER2 nanoCAR T cells, we saw a lower killing efficiency
by the tandem nanoCAR T cells for single CD20 positive Jurkat cells. However, the killing efficiency
was restored when both HER2 and CD20 were present on the Jurkat cells (Figure 3A).
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Figure 2. Characterization of the transgenic Jurkat lines expressing CD20, HER2, or both, that are used
as target cells in the experiments shown in Figure 3. Jurkat cells were retrovirally transduced with the
sequences coding for CD20 of for HER2 truncated at position 695 (HER2∆695). The transgenic Jurkat
cells were stained for CD20 and HER2 expression and analyzed by flowcytometry. As antigen negative
control, non-transduced Jurkat cells (NTD) were used, MFIs are shown for each Jurkat clone.
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Figure 3. Validation of the monospecific and tande nanoCARs. (A) Cell lysis of Jurkat target cells
expressing CD20, HER2, or both, after 4 h co-incubation with T cells expressing the monospecific
or tandem nanoCAR in different effector-target ratios. Reported values are means of duplicate
determinations with error bars indicating the standard deviation. Results are representative of two
independent experiments, performed with three different donors. (B) Cytokine production of nanoCAR
transduced T cells was analysed by intracellular staining after co-incubation with Jurkat cells. Mean
percentages of interferon-γ (IFN-γ), interleukin-2 (IL-2) and tumor necrosis factor-α (TNF-α) positive
cells are shown. Error bars represent standard deviations. The data is representative of two independent
experiments, performed with three different donors.
Next, we examined the cyt ction of transduc d a d non-transduced T cells after
challenging them with the diff r t J r t li es. Jurkat cells w re co-incubated for 16 hr with T cells.
Subseque tly, the T cells were labelled for intracellular interferon-γ (IFN-γ), interleukin-2 (IL-2) and
tumor necrosis factor α (TNF-α). The transduced T cells were able to produce IFN-γ, IL-2 and TNF-α.
Both single antigen expressing Jurkat cell lines were capable of stimulating mono- and bispecific T cells.
The tandem nanoCAR T cells showed a strong response when stimulated with HER2positive Jurkat
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cells but the response on single CD20 positive cells was lower than the response of the monospecific
nanoCAR T cells. This observation was in line with the cytotoxicity experiments (Figure 3B).
Both the cytokine secretion and cytotoxicity assay clearly showed that the bivalent nanobody
based CAR acts in a Boolean OR-gate fashion. However, we observed no additive or synergistic effects.
Furthermore, the functionality of the tandem nanoCAR T cells was lower, compared to the CD20
mono-specific nanoCAR T cells, when these were stimulated with CD20 single positive Jurkat cells.
We wondered whether the absence of an additive effect could be the result of impaired
simultaneous binding of CD20 and HER2 by the tandem nanoCAR. We generated the respective
monospecific and bispecific nanobodies and tested these in a flowcytometric binding assay. While
the CD20 nanobody in the tandem CAR had a higher binding affinity for CD20 (4.9 × 10−9 M for
the monospecific and 8.1 × 10−9 M for the bispecific nanobody), the affinity of the HER2 nanobody
domain dropped from 4.0 × 10−10 M to 3.0 × 10−9 M. When the nanobody constructs were tested for
binding with both antigens simultaneously, we did not detect an additive effect (Figure 4A). While the
affinity for HER2 dropped, we observed no difference in killing potential of the tandem nanoCAR for
single HER2 positive Jurkat cells, compared with the lytic activity of the HER2 nanoCAR transduced T
cells. However, while the affinity for CD20 increased when targeted by our tandem nanoCAR, we saw
a decrease in lytic potential when tested against a single CD20 positive Jurkat cell line, compared with
the monospecific CD20 nanoCAR (Figures 3A and 4B). In conclusion, we did not find a correlation
between affinity and functionality.
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Figure 4. It is not the affi it of the different CAR str ctures that affects their function, but rather,
the CAR structure. (A) Affinity determination of the monospecific of bispecific nanobody constructs.
Affinities are shown in molar concentration. (B) Lysis by mono-specific or tandem nanoCAR T cells
against Jurkat target cells expressing one antigen. Data show the mean values of duplicates and are
representative of three independent experiments on three different donors.
We have shown for the first time that it is possible to generate a bispecific CAR based on
nanobodies. This CAR act as a typical Boolean OR-gate: one of the two antigens is sufficient to
elicit robust T cell activation, cytokine production and cytotoxic activity.
However, some optimization remains necessary. The long hinge lama linker that is used here to
connect both nanobodies is bulkier and less flexible than the standard glycine-serine hinges (Figure 1).
However, the linker is flexible enough to allow both nanobodies to move freely [37]. As a result,
it is unlikely that one nanobody interferes with the binding of the other to its antigen. This is in line
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with the affinity determinations in which we observed binding of either CD20 or HER2, although an
additive effect was not found. Furthermore, the nanoCAR T cells stimulated with HER2 positive target
cells elicited a stronger T cell response than when stimulated with CD20 positive cells, despite similar
binding affinity of the tandem nanoCAR for CD20 and HER2. This could be due to a suboptimal
distance between the cell membranes of the CAR T effector cells and target cells at the immunological
synapse, induced by the binding of the tandem nanoCAR to CD20 and HER2. Different groups have
shown that the distance between the CAR T cell and their target cell is critical for T cell functionality.
This distance is determined by the length of the spacer domain and the epitope location targeted
by the antigen binding domain. If a monospecific CAR recognizes an epitope located close to the
cell membrane of the target cell, then T cell activation is optimal when the CAR is designed with
a long spacer domain. In contrast, when the targeted epitope is located more distally from the cell
membrane, a short spacer seems to be optimal for T cell function [38–41]. This can be explained
by the kinetic segregation model. According to this model, the immunological synapse, formed by
the interaction of a T cell with the target cell has to generate close contact zones, able to physically
exclude the large inhibitory CD45 or CD148 phosphatases. If these close contact zones do not form,
inhibitory phosphatases enter the synapse and abort T cell activation [42–44]. We used a long spacer
in the tandem nanoCAR. The distance from the HER2 nanobody domain to the cell membrane of
the T cells is the length of the spacer, while the distance from the CD20 nanobody domain to the cell
membrane is the combined length of the spacer, the HER2 nanobody and the linker between the HER2
and CD20 nanobody. The long distance from the CD20 nanobody to the cell membrane could result in
an immunological synapse that is too large. Therefore, inhibitory phosphatases may enter the synapse
and disturb T cell activation.
One shortcoming of our experiments is the sole use of in vitro functional tests. These assays do
not always predict in vivo effectiveness of multiple antigen targeted therapeutics. Therefore, in vivo
experiments should be carried out [14].
This tandem CD20 HER2 nanoCAR was designed as proof of principle CAR. Tandem nanoCARs
for therapeutic purposes should be directed to relevant targets, such as CD19, CD20 and/or CD22 for
the treatment of B cell leukemias or CLL-1, CD33 and/or CD123 for the treatment of acute myeloid
leukemia. For the design of these tandem nanoCARs, one should consider the structure of the targeted
proteins and the CAR architecture. For instance, CD20 is a multipass transmembrane protein with
no protruding extracellular domains [45], while CD19, a single pass membrane protein and member
of the Ig like protein family, is a typical transmembrane protein, consisting of a large extracellular
domain [46]. Construction of a tandem nanoCAR should take into account spacer length, epitope
location, linker length and position of the nanobodies in the CAR construct (Figure 1). Since CD20
is a multipass protein, the epitope of the generated nanobody will be close to the cell membrane of
the leukemic cell, while the epitope of a CD19 specific nanobody may be more distal to the leukemic
cell membrane. Therefore, the CD20 nanobody domain should be at the N-terminal side of the CAR.
The CD19 nanobody domain, on the other hand, should be close to the cell membrane of the T cell and
therefore connected to the cell membrane with a short spacer domain, such as a CD8α-hinge or an
IgG4-hinge region. The linker length between the CD20 and CD19 nanobodies should be determined
empirically. All these variables should be tested in vitro and eventually, in vivo.
In conclusion, we have shown that bivalent nanobody based CARs are easily designed, expressed
and are functional. An optimally designed nanoCAR may be advantageous in the treatment of
leukemias as it should be able to prevent antigen escape.
3. Materials and Methods
3.1. Culture of Cell Lines
All the Jurkat lines were cultured, as per American Type Culture Collection (ATCC, Manassas,
Virginia) recommendations, in standard complete medium, consisting of IMDM (Gibco, Invitrogen,
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Merelbeke, Belgium), supplemented with 10% fetal calf serum (FCS, Gibco, Invitrogen), 2 mM
L-glutamine (Gibco, Invitrogen), 100 IU/mL penicillin (Gibco, Invitrogen) and 100 IU/mL streptomycin
(Gibco, Invitrogen) (complete IMDM, cIMDM). The JY cell line, a human HLA-A2+ Eppstein Barr virus
(EBV)-immortalized B-cell line, was obtained from the ATCC and cultured in cIMDM.
3.2. Production of Retroviral Vectors
The different constructs, as shown in Figure 1A, were generated by cloning a gBlock (IDT) coding
for the murine kappa leader and the antigen-binding domain into the LZRS-IRES-eGFP vector that
already contained a second generation CAR, using BamHI [47]. Viral particles were produced using
the Phoenix packaging cell line. Retroviral supernatant was collected at day 14 after transfection and
puromycin selection and frozen until use.
3.3. Generation of NanoCAR Expressing Human T Cells
Buffy coats from healthy donors were obtained from the Belgian Red Cross and used following
the guidelines of the Medical Ethical Committee of Ghent University Hospital (CG20171208A,
8 December 2017), after informed consent had been obtained, in accordance with the Declaration
of Helsinki. Mononuclear cells were isolated by Lymphoprep (Axis-shield, Dundee, UK) gradient
centrifugation. T cells were enriched by magnetic activated cell sorting using Streptavidin microbeads
(MACS beads, Milteyni, Leiden, The Netherlands), after staining with homemade CD4-biotin (OKT4)
and CD8-biotin (OKT8). T cells were stimulated with CD3/CD28 T-cell activation Dynabeads
(Life Technologies, Merelbeke, Belgium) at a 1:1 bead:cell ratio, in cIMDM medium, in the presence
of 10 ng/mL IL-12, and retrovirally transduced on retronectin coated plates (TaKaRa, Saint-Germain-
en-Laye, France) 72 h after stimulation. Cells resuspended in retroviral supernatant were centrifuged
for 90 min at 2300 rpm at 32 ◦C. Dynabeads were removed before transduction.
Transduced cells were detected by eGFP expression or by an anti-IgG antibody directed against the
human IgG1 spacer domain present in the extracellular domain of both CARs. Transduced cells were
sorted and expanded on irradiated allogenic feeder cells, consisting of a mixture of 40-Gy irradiated
peripheral blood mononuclear cells and 50-Gy irradiated JY cells. Cells were cultured in cIMDM
(Gibco, Merelbeke, Belgium), supplemented with 1 µg/mL phytohemagglutinin (PHA, Sigma–Aldrich,
Diegem, Belgium). IL-2 (40 IU/mL) (Roche, Vilvoorde, Belgium) was added on day 5 and day 10. Cells
were restimulated every 7–14 days.
3.4. Flow Cytometry and Antibodies
Staining of surface markers was performed in DPBS with 1% FCS using the antibody concentration
recommended by the supplier. Intracellular staining was performed following the supplier’s protocol
using BD Cytofix&Cytoperm (BD Biosciences, Erebodegem, Belgium). Flow cytometric analysis was
performed on the LSR II and cell sorting on the ARIA II (both BD Biosciences). All populations analyzed
were devoid of dead cells based on propidium iodide negativity and of doublets based on FSC-A
FSC-W ratios. The following anti-human monoclonal antibodies were used: PE-conjugated—IgG-Fc
(eBioscience, Merelbeke, Belgium); allophycocyanin (APC)-conjugated—CD20 (BD Biosciences), HER2
(BD Biosciences), CD8α (BD Biosciences), CD4 (BD Biosciences); APC-Cy7-conjugated—CD8α (BD
Biosciences); biotine-conjugated—CD4 (OKT4, homemade), CD8 (OKT8, homemade).
3.5. 51Chromium Release Assay
Target cells were labelled with 51Chromium (Perkin Elmer, Zaventem, Belgium) for 90 min
at 37 ◦C, washed and added at 103 cells per well to various ratios of effector T cells in 96 well
V-bottomed plates (NUNC, Thermo Fisher Scientific, Merelbeke, Belgium). After 4 h of co-incubation,
the supernatant was harvested and measured in a 1450 LSC & Luminescence Counter (Perkin Elmer,
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Zaventem, Belgium). Specific lysis was calculated, as follows: (experimental release–spontaneous
release)/(maximal release–spontaneous release) × 100%.
3.6. Flowcytometric Determination of Cytokine Production
Two hundred thousand feeder culture expanded T cells were stimulated by co-incubation with
Jurkat lines expressing the relevant antigen at 105 cells in 96-well U-bottom plates. After 1 h of
stimulation, BD GolgiPlug (BD Biosciences) was added and after an additional 16 h of stimulation,
the cells were harvested, permeabilized, labelled and analyzed by flowcytometry for cytokine
expression using TNF-α-PE-Cy7, IFN-γ-PE and IL-2-APC (all three from BD Biosciences).
3.7. Affinity Determination
Jurkat lines expressing CD20, HER2 or both were coated in 96-well U-bottom plates (NUNC,
Thermo Fisher Scientific) and nanobody was added in different dilutions. After incubation for 30 min
at 4 ◦C, cells were labelled with mouse anti-FLAG antibody (Sigma-Aldrich) for 30 min at 4 ◦C, washed
and labelled with goat anti-mouse-APC (Jackson ImmunoResearch Laboratories, St-Martens-Latem,
Belgium) for 30 min at 4 ◦C. Cells were analyzed by flowcytometry after a final wash step.
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